Linaprazan Glurate
Severe Gastroesophageal Reflux Disease (GERD)
Key Facts
About Cinclus Pharma
Cinclus Pharma is a private, clinical-stage biotech targeting the large and underserved market for gastroesophageal reflux disease (GERD) with its novel potassium-competitive acid blocker (PCAB), linaprazan glurate. The drug candidate has completed Phase II trials and represents a potential paradigm shift in acid suppression therapy, offering a differentiated mechanism of action and pharmacokinetic profile. The company is in an intensive development phase, scaling its organization to advance its lead asset toward late-stage trials and eventual global registration.
View full company profileAbout Cinclus Pharma
Cinclus Pharma is a private, clinical-stage biotech targeting the large and underserved market for gastroesophageal reflux disease (GERD) with its novel potassium-competitive acid blocker (PCAB), linaprazan glurate. The drug candidate has completed Phase II trials and represents a potential paradigm shift in acid suppression therapy, offering a differentiated mechanism of action and pharmacokinetic profile. The company is in an intensive development phase, scaling its organization to advance its lead asset toward late-stage trials and eventual global registration.
View full company profile